CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?
CareDx (CDNA) shares rose 13% to $61.37 on high volume, following a price target increase to $74 by BTIG. Q2 2026 revenue grew 52% YoY, with testing services up 61%. Q3 earnings are expected at $0.24 per share, down 14.3% YoY, and revenue at $122.35M, up 22.3% YoY. The stock has a Zacks Rank of #2 (Buy). Charles River Laboratories (CRL), another medical services company, closed up 6.2% at $294.44, with a Zacks Rank of #2 (Buy).
How this was made
The 30-second read
Why it matters
The upgrade could attract momentum traders, but lack of earnings estimate change may limit durability.
Market read
Short-term bullish catalyst for CDNA; peers may see modest spillover.
What to watch
No change in earnings estimates; the move relies solely on analyst opinion.
Background
CareDx reported a 13% price increase after BTIG raised its target price, while revenue growth expectations remain strong.
Ticker impact
BTIG raised its price target to $74 from $60, triggering a 13% intraday jump in CareDx shares.
Potential continued upside if momentum sustains, but limited by lack of new earnings data.
Price target lift is fresh news; however, no earnings revision accompanies it, so move may be short-lived.
Market effects
Positive sentiment may spill to other molecular diagnostics stocks.
Limited to US biotech sector.
Minimal global impact.
Counterpoint
The price jump may be overbought without earnings support; caution on pullback.
Key entities
- CompanyCareDx, Inc.
Molecular diagnostics firm (ticker CDNA).
- Analyst FirmBTIG
Raised CareDx price target to $74.
